Stifel resumed coverage of Insulet (PODD) with a Buy rating and $370 price target The firm expects the company’s current momentum to continue, creating upward revisions to its guidance. Stifel’s survey work suggests the type 2 insulin-intensive opportunity “has legs” for pump providers and that the patch is the preferred form factor, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $365 from $350 at RBC Capital
- Insulet price target raised to $399 from $353 at Canaccord
- Trump announces $15B libel suit against New York Times: Morning Buzz
- Trump announces $15 libel suit against New York Times: Morning Buzz
- Insulet Appoints New CFO Amid Revenue Growth